Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3)

This study has been completed.
Information provided by (Responsible Party):
Novo Nordisk A/S Identifier:
First received: June 20, 2013
Last updated: September 23, 2016
Last verified: September 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2015
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: September 23, 2016